SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): August 31, 2006
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction
|(Commission File Number)|| |
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrants telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 2.02. Results of Operations and Financial Condition.
On August 31, 2006, Bristol-Myers Squibb Company (the Company) posted additional supplemental information on the Companys website at www.bms.com. This additional supplemental information includes net sales, months on hand, and estimated demand information for key products and growth drivers as of June 30, 2006 for the Companys International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of March 31, 2006, June 30, 2005 and March 31, 2005. The additional supplemental information is furnished and incorporated by reference as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
99.1. Additional supplemental information posted on Bristol-Myers Squibb Companys website at www.bms.com
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|BRISTOL-MYERS SQUIBB COMPANY|
|Dated: August 31, 2006||By:|
|Exhibit No.|| |
|99.1||Additional supplemental information posted on Bristol-Myers Squibb Companys website at www.bms.com|